Castle Biosciences Q2 EPS $(0.70) Beats $(1.01) Estimate, Sales $50.14M Beat $43.51M Estimate
Portfolio Pulse from totan@benzinga.com
Castle Biosciences reported Q2 losses of $(0.70) per share, beating the analyst consensus estimate of $(1.01) by 30.69%. This is a 9.09% increase over losses from the same period last year. The company also reported quarterly sales of $50.14 million, beating the analyst consensus estimate of $43.51 million by 15.23%. This is a 43.92% increase over sales from the same period last year.
August 04, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Castle Biosciences reported better than expected Q2 results with losses per share and sales beating analyst estimates.
Castle Biosciences reported Q2 losses per share of $(0.70), which is better than the analyst consensus estimate of $(1.01). This is a positive signal as it shows the company's losses are less than expected. Additionally, the company's sales of $50.14 million beat the analyst consensus estimate of $43.51 million, indicating strong revenue growth. These factors are likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100